As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ap­proval

A post-ap­proval com­mit­ment test­ing Imfinzi in a late-stage blad­der can­cer pop­u­la­tion has gone pear-shaped for As­traZeneca, as the check­point in­hibitor failed to help pa­tients live longer in an open-la­bel piv­otal study.

Back in 2017, the PD-L1 drug was grant­ed ac­cel­er­at­ed ap­proval by the FDA for pa­tients with lo­cal­ly ad­vanced or metasta­t­ic blad­der can­cer whose dis­ease has per­sist­ed de­spite plat­inum-con­tain­ing chemother­a­py on the ba­sis of Phase I/II da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.